{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:01:31Z","timestamp":1787785291073,"version":"build-2784847793"},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thorac Cardiovasc Surg"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Objective of this study was to assess postoperative morbidity and mortality as well as recurrence-free and overall survival in patients with thymic malignancies and pleural dissemination undergoing surgical cytoreduction and hyperthermic intrathoracic chemotherapy (HITOC).<\/jats:p><jats:p>\n          Methods\u2003Retrospective study between September 2008 and December 2017 with follow-up analysis in May 2018.<\/jats:p><jats:p>\n          Results\u2003A total of 29 patients (male: n\u2009=\u200917) with thymic malignancies and pleural spread (primary stage IVa: n\u2009=\u200911; pleural recurrence: n\u2009=\u200918) were included. Surgical cytoreduction was performed via pleurectomy\/decortication (P\/D; n\u2009=\u200911), extended P\/D (n\u2009=\u200915), and extrapleural pneumonectomy (EPP; n\u2009=\u20093). These procedures resulted in 25 (86%) patients with macroscopically complete (R0\/R1) resection. Intraoperative HITOC was performed for 60\u2009minutes at 42\u00b0C either with cisplatin (100\u2009mg\/m2 body surface area [BSA] n\u2009=\u20098; 150\u2009mg\/m2 BSA n\u2009=\u20096; 175\u2009mg\/m2 BSA n\u2009=\u20091) or with a combination of cisplatin (175\u2009mg\/m2 BSA)\/doxorubicin (65\u2009mg; n\u2009=\u200914). Postoperative complications occurred in nine patients (31%). Cytoprotective therapy resulted in lower postoperative creatinine levels (p\u2009=\u20090.036), and there was no need for temporary dialysis in these patients. The 90-day mortality rate was 3.4%, as one patient developed multiple organ failure. While recurrence-free 5-year survival was 54%, an overall 5-year survival rate of 80.1% was observed. Survival depended on histological subtype (p\u2009=\u20090.01).<\/jats:p><jats:p>\n          Conclusion\u2003Surgical cytoreduction with HITOC is feasible in selected patients and offers encouraging survival rates. The application of cytoprotective agents appears to be effective for the prevention of postoperative renal insufficiency.<\/jats:p>","DOI":"10.1055\/s-0039-1700883","type":"journal-article","created":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:26:53Z","timestamp":1573864013000},"page":"157-164","source":"Crossref","is-referenced-by-count":14,"title":["Surgical Cytoreduction and HITOC for Thymic Malignancies with Pleural Dissemination"],"prefix":"10.1055","volume":"69","author":[{"given":"Till","family":"Markowiak","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Medical Center Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Neu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Medical Center Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Khalid Afeen","family":"Ansari","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Medical Center Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gro\u00dfer","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hospital Barmherzige Br\u00fcder Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Klinkhammer-Schalke","sequence":"additional","affiliation":[{"name":"Tumor Center, University Institute of Quality Assurance and Health Services Research, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Stefan","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Medical Center Regensburg, Regensburg, Germany"},{"name":"Department of Thoracic Surgery, Hospital Barmherzige Br\u00fcder Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ried","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, University Medical Center Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.athoracsur.2003.10.001","article-title":"Thymic tumors","volume":"77","author":"F C Detterbeck","year":"2004","journal-title":"Ann Thorac Surg"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0030-1271010","article-title":"Surgical resection of thymoma still represents the first choice of treatment","volume":"60","author":"M Ried","year":"2012","journal-title":"Thorac Cardiovasc Surg"},{"issue":"08","key":"ref3","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1200\/JCO.2004.10.113","article-title":"Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis","volume":"22","author":"P Str\u00f6bel","year":"2004","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.athoracsur.2009.08.074","article-title":"Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery","volume":"89","author":"S Margaritora","year":"2010","journal-title":"Ann Thorac Surg"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/ejcts\/ezx090","article-title":"Surgical therapy of thymic tumours with pleural involvement: an ESTS Thymic Working Group Project","volume":"52","author":"B Moser","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"issue":"07","key":"ref6","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/JTO.0b013e3181a4b8e0","article-title":"The management of thymoma: a systematic review and practice guideline","volume":"4","author":"C B Falkson","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/ejcts\/ezs418","article-title":"Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience","volume":"43","author":"M Ried","year":"2013","journal-title":"Eur J Cardiothorac Surg"},{"issue":"09","key":"ref8","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ejso.2006.03.049","article-title":"Debulking surgery for advanced thymoma","volume":"32","author":"H C Liu","year":"2006","journal-title":"Eur J Surg Oncol"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5761\/atcs.oa.17-00108","article-title":"Role of surgery in the treatment of Masaoka Stage IVa thymoma","volume":"24","author":"E Kaba","year":"2018","journal-title":"Ann Thorac Cardiovasc Surg"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0022-5223(97)70399-4","article-title":"Recurrence of thymoma: analysis of clinicopathologic features, treatment, and outcome","volume":"113","author":"E Ruffini","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1378\/chest.121.2.480","article-title":"Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma","volume":"121","author":"E de Bree","year":"2002","journal-title":"Chest"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/00000658-199910000-00012","article-title":"Clinical and pathologic predictors of survival in patients with thymoma","volume":"230","author":"K B Wilkins","year":"1999","journal-title":"Ann Surg"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.02.014","article-title":"Intra-thoracic chemo-hyperthermia for pleural recurrence of thymoma","volume":"108","author":"J M Maury","year":"2017","journal-title":"Lung Cancer"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0003-4975(01)02786-2","article-title":"Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread","volume":"72","author":"Y Refaely","year":"2001","journal-title":"Ann Thorac Surg"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jtcvs.2012.10.013","article-title":"Resection and heated pleural chemoperfusion in patients with thymic epithelial malignant disease and pleural spread: a single-institution experience","volume":"145","author":"A Yellin","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jtcvs.2008.07.055","article-title":"A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma","volume":"137","author":"L Zellos","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"09","key":"ref17","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jtho.2018.04.032","article-title":"A phase I trial of surgical resection and intraoperative hyperthermic cisplatin and gemcitabine for pleural mesothelioma","volume":"13","author":"B M Burt","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtcvs.2012.12.037","article-title":"Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection","volume":"145","author":"D J Sugarbaker","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.2005.04.6813","article-title":"Phase I to II study of pleurectomy\/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma","volume":"24","author":"W G Richards","year":"2006","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/ejcts\/ezv039","article-title":"Pleural recurrence of thymoma: surgical resection followed by hyperthermic intrathoracic perfusion chemotherapy","volume":"49","author":"M C Ambrogi","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0022-5223(99)70297-7","article-title":"Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study","volume":"117","author":"G B Ratto","year":"1999","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"07","key":"ref22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/jso.23321","article-title":"Local and systemic exposure of cisplatin during hyperthermic intrathoracic chemotherapy perfusion after pleurectomy and decortication for treatment of pleural malignancies","volume":"107","author":"M Ried","year":"2013","journal-title":"J Surg Oncol"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0002-9343(78)90825-2","article-title":"Platinum nephrotoxicity","volume":"65","author":"N E Madias","year":"1978","journal-title":"Am J Med"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jtcvs.2009.02.046","article-title":"Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study","volume":"138","author":"T R Tilleman","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00520-015-2978-0","article-title":"Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy","volume":"24","author":"T McKibbin","year":"2016","journal-title":"Support Care Cancer"},{"issue":"14","key":"ref26","first-page":"3451","article-title":"Direct amifostine effect on renal tubule cells in rats","volume":"59","author":"K J Weichert-Jacobsen","year":"1999","journal-title":"Cancer Res"},{"issue":"06","key":"ref27","first-page":"1525","article-title":"A single institutional experience of surgically resected thymic epithelial tumors over 10 years: clinical outcomes and clinicopathologic features","volume":"19","author":"B K Kim","year":"2008","journal-title":"Oncol Rep"},{"issue":"07","key":"ref28","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00268-009-0069-4","article-title":"Thymoma with dissemination: efficacy of macroscopic total resection of disseminated nodules","volume":"33","author":"M Yano","year":"2009","journal-title":"World J Surg"},{"issue":"S 02","key":"ref29","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/JTO.0000000000000290","article-title":"The IASLC\/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors","volume":"9","author":"F C Detterbeck","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.jtcvs.2017.10.070","article-title":"Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: a 10-year experience","volume":"155","author":"M C Ambrogi","year":"2018","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["The Thoracic and Cardiovascular Surgeon"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0039-1700883.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T06:56:35Z","timestamp":1615877795000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0039-1700883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":30,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2021,3,14]]},"published-print":{"date-parts":[[2021,3]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0039-1700883","relation":{},"ISSN":["0171-6425","1439-1902"],"issn-type":[{"value":"0171-6425","type":"print"},{"value":"1439-1902","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]}}}